S-1/A: PMGC Holdings S-1/A: Strategic Shifts & Capital Raises

PMGC Holdings Inc. filed an S-1/A detailing its transformation into a diversified holding company with a focus on biotechnology and manufacturing acquisitions, alongside significant capital raising activities.

Summary

• PMGC Holdings Inc. has transitioned from a skincare development company to a diversified holding company, managing a portfolio of four wholly-owned subsidiaries: Northstrive Biosciences Inc. (biopharmaceutical), PMGC Capital LLC (multi-strategy investment), Pacific Sun Packaging, Inc. (specialty packaging), and AGA Precision Systems LLC (CNC machine shop).
• The company completed the divestiture of its Elevai Skincare Inc. business on January 16, 2025, to focus resources on larger markets with unmet needs, particularly in biotechnology.
• Northstrive Biosciences is advancing EL-22, an engineered probiotic for muscle preservation during weight loss treatments (including GLP-1 receptor agonists), which completed a Phase 1 clinical trial in South Korea showing promising safety and tolerability.
• PMGC Capital is focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets.
• Recent acquisitions include Pacific Sun Packaging Inc. (July 7, 2025, for $1.148 million cash plus potential $250,000 earnout) and AGA Precision Systems LLC (July 18, 2025, for $650,000 cash), and Indarg Engineering, Inc. (October 26, 2025, for $548,000, including a $170,000 promissory note).
• The company executed several financing activities, including a warrant inducement agreement on August 22, 2025, generating $1,668,218.50 gross proceeds, and an equity line of credit on September 23, 2025, for up to $20 million, with an initial $5 million pre-paid purchase yielding $3.99 million net proceeds.
• A 3.5-for-1 reverse stock split was effective on September 2, 2025, following a 1-for-7 reverse split on March 10, 2025, and a 1-for-200 reverse split on November 27, 2024, resulting in a combined 1-for-4,900 reverse stock split.
• Authorized common stock was increased from 81,632,654 to 2,000,000,000 shares on September 15, 2025.
• The company reported a net loss from continuing operations of $4,776,319 for the nine months ended September 30, 2025, compared to $2,298,885 for the same period in 2024.
• As of September 30, 2025, the company had cash of $7,700,562 and an accumulated deficit of $18,034,757, with a net working capital of $4,310,939.

Sentiment

Score: 3

Explanation: The company is undergoing a significant strategic transformation with promising biotechnology assets and recent acquisitions, which are positive. However, the persistent and increasing net losses, the explicit 'going concern' warning, and heavy reliance on dilutive financing methods (equity line, warrant inducements, ATM) indicate substantial financial challenges and high risk, leading to a low-to-moderate sentiment score.

Positives

• Successful divestiture of the skincare business allows for focused resource allocation to larger, high-growth markets like biotechnology.
• Acquisition of Pacific Sun Packaging Inc. and AGA Precision Systems LLC diversifies the company's portfolio into specialty packaging and precision machining, adding revenue-generating operations.
• Northstrive Biosciences' lead asset, EL-22, has completed a Phase 1 clinical trial with promising safety and tolerability results, positioning it for further development in the large obesity market.
• Multiple capital raising activities, including a warrant inducement agreement ($1.67 million gross proceeds) and an equity line of credit ($3.99 million net proceeds from initial pre-paid purchase), have improved liquidity.
• The company has a comprehensive intellectual property portfolio, including patents and patent applications for its biotechnology assets, which may prevent others from commercializing similar products.

Negatives

• The company's financial statements have been prepared on a going-concern basis, indicating substantial doubt about its ability to continue operations due to recurring losses and limited revenue.
• Significant net losses continue, with $4,776,319 for the nine months ended September 30, 2025, and $6,245,737 for the year ended December 31, 2024.
• Operating expenses increased significantly, with consulting fees rising by $582,585 and office and administration expenses by $807,539 for the nine months ended September 30, 2025, compared to the prior year.
• The company used $4,183,881 in cash for operating activities during the nine months ended September 30, 2025.
• Voting control is highly concentrated, with two entities wholly owned by the CEO and Chairman holding approximately 89.55% of the company's voting capital stock, limiting influence for other investors.
• The equity line of credit involves potentially dilutive share issuances at a discount to VWAP and includes a 120% prepayment penalty, which could be detrimental to existing shareholders.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, limited revenue, and reliance on external funding.
• Inability to secure sufficient additional funds through debt or equity financing could force delays, reductions, or elimination of planned operations, including R&D and acquisitions.
• Failure to achieve or maintain profitability in the future, as the company has incurred net losses since inception.
• Challenges in effectively managing future growth, especially if rapid, could adversely affect business, financial condition, and results of operations.
• Loss of key personnel or inability to attract and retain qualified personnel, particularly in executive leadership, capital markets, M&A, regulatory oversight, and financial structuring, could disrupt business execution.
• The acquisition strategy exposes the company to significant risks, including integration difficulties, diversion of management attention, unanticipated costs, and failure to realize anticipated benefits.
• Diversification across multiple industries may increase exposure to various regulatory environments, competitive pressures, and operational challenges.
• Inability to finance future acquisitions or expansions could limit growth prospects and adversely affect financial performance, potentially leading to significant dilution for stockholders if equity is issued.
• The manufacturing sector, where some subsidiaries operate, is cyclical and sensitive to economic conditions, raw material costs, and supply chain disruptions.
• Future sales by existing stockholders or the perception of such sales could depress the price of common stock and impair the ability to raise capital.
• Issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to existing stockholders.
• Management will have broad discretion over the use of proceeds from warrant exercises, which may not be invested successfully or in ways shareholders agree with.
• The biotechnology industry is highly competitive, with major players developing obesity treatments and muscle preservation therapies, posing a challenge for Northstrive Biosciences' assets.
• Regulatory bodies may require preclinical bridge studies for EL-22 to pivot from DMD to obesity indications, potentially delaying IND clearance and clinical trials.

Future Outlook

The company intends to focus on growing revenue through PMGC Capital's investment activities, establishing new wholly-owned subsidiaries for biotechnology assets, utilizing clinical validation studies, advancing EL-22 towards an IND application with the FDA, pursuing additional acquisitions, and evaluating potential spin-offs of subsidiaries to unlock shareholder value. The company believes it has sufficient funds for current operations for at least the next 12 months but may seek additional capital to accelerate plans.

Management Comments

• The Skincare asset divestiture enables us to dedicate more resources and time to advancing our initiatives and assets in larger markets with unmet needs, creating greater growth opportunities for the Company and its shareholders.
• Our efforts will focus on the clinical development of biotechnology assets through NorthStrive Biosciences Inc. Moreover, this strategic shift positions us to actively explore and execute potential business acquisitions and high-value biotechnology assets, further strengthening our portfolio and driving long-term growth.
• We believe that EL-22 has the potential to treat obesity in combination with GLP-1 receptor agonists by preserving muscle mass while decreasing fat mass.
• We believe this urgent unmet medical need could be addressed by both EL-22 and EL-32, that may effectively prevent the loss of muscle mass and increase the fat loss experienced by older patients receiving GLP-1 drugs for the treatment of obesity.

Industry Context

The company is strategically shifting its focus to the rapidly growing biotechnology market, particularly the anti-obesity drug sector, which Goldman Sachs projects could reach $100 billion by 2030. This move positions PMGC Holdings to address the unmet need for muscle preservation therapies alongside GLP-1 receptor agonists, a significant challenge with current weight-loss drugs. The acquisitions in specialty packaging and precision machining also align with broader trends in advanced manufacturing and supply chain security, particularly in aerospace, defense, and IT hardware, where demand for high-precision components and domestic production is increasing.

Comparison to Industry Standards

• Northstrive Biosciences' EL-22 and EL-32 are positioned as oral myostatin formulations, which would be a first-in-class approach compared to existing injectable GLP-1 drugs like Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro/Zepbound, and other muscle preservation therapies from companies like Versanis Bio (Eli Lilly), Pfizer, Biohaven, Scholar Rock, and Veru.
• The company's gross margin percentage of 27% for the nine months ended September 30, 2025, is driven by newly acquired subsidiaries, with Pacific Sun Packaging at 18% (45% normalized for fair value adjustment) and AGA Precision Systems at 43%. Specific industry benchmarks for these niche manufacturing sectors are not provided in the filing for direct comparison, but a 45% normalized gross margin for specialty packaging could be competitive.
• The company's reliance on non-employee consultants for executive leadership (CEO, CFO, Chairman) is a less common structure for publicly traded companies, potentially differing from industry standards for corporate governance and executive compensation in established firms.

Management Changes

Corporate Governance

Legal Proceedings

• As of December 31, 2024, the company had an ongoing dispute that arose in the normal course of business. In February 2025, a settlement agreement was reached to resolve all claims, with amounts payable included in accounts payable and accrued liabilities as of December 31, 2024, and paid in full by September 30, 2025.
• As of September 30, 2025, the company had another ongoing dispute in the normal course of business, with mediation discussions underway. The likelihood of an unfavorable outcome or potential loss amount is not yet predictable.

Related Party Transactions

• The company incurred consulting fees of $391,333 in 2024 and $110,000 in 2023 to GB Capital Ltd., wholly owned by CEO/CFO Graydon Bensler. From January 1, 2025, to November 25, 2025, $218,332.64 in consulting fees were paid, with $158,400 due in contract performance bonuses.
• The company incurred consulting fees of $365,900 in 2024 and $120,000 in 2023 to Northstrive Companies Inc., wholly owned by Chairman Braeden Lichti. From January 1, 2025, to November 25, 2025, $301,400 was paid, with $158,400 due in bonus payments.
• On July 25, 2025, the company entered into a Secondment Agreement with GB Capital Ltd., agreeing to reimburse GB Capital for seconded employees' costs (salary, benefits, car, office space, mobile phone, hiring fees) plus a 30% fee on aggregate employment costs.
• On May 7, 2025, the company entered into a Secondment Agreement with Northstrive Companies Inc., with similar reimbursement terms for seconded employees' costs plus a 30% fee on aggregate employment costs.
• On October 16, 2025, Amendment No. 1 to both Secondment Agreements (GB Capital and Northstrive) clarified effective dates, employee classification (exempt/non-exempt), eligibility for group health plans, and milestone-driven bonuses.
• On October 16, 2025, Amendment No. 4 to both Consulting Agreements (GB Capital and Northstrive) added monthly housing reimbursement ($8,000 for GB Capital), clarified independent contractor status, and granted express authorization to enter contracts on behalf of the company.
• On August 12, 2025, Amendment No. 3 to both Consulting Agreements (GB Capital and Northstrive) introduced 'Acquisition Awards' for consummated acquisitions, ranging from 5% to 8% of the acquisition value (plus a potential 1% discretionary bonus), payable in cash, RSUs, or restricted stock.
• On March 26, 2025, shareholders approved the issuance of 3,036,437 shares of Series B Preferred Stock to GB Capital Ltd. and 3,336,437 shares to Northstrive Companies Inc. as signing bonuses (totaling $150,000 in accrued bonuses).
• As of September 30, 2025, $315,097 was due to companies controlled by Braeden Lichti, and $170,498 was due to Graydon Bensler's entity for consulting fees and expenses.
• The company had an Unsecured Revolving Line of Credit Promissory Note for $200,000 with NorthStrive Fund II LP (controlled by Braeden Lichti), which was repaid in full in 2024 with $40,000 interest.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing equity raises (equity line, ATM, warrant exercises) and reverse stock splits. Voting power is highly concentrated with related parties. The 'going concern' warning indicates substantial risk to investment value. Potential for long-term value creation exists if biotechnology assets succeed and acquisitions are integrated profitably.
• **Employees**: The company has 17 full-time and 1 part-time employee. Recent terminations of CMO and CCO as part of restructuring may impact morale. Secondment agreements with related parties for key personnel indicate a hybrid employment model. The 2025 Equity Incentive Plan aims to attract and retain talent.
• **Customers**: Acquisitions of Pacific Sun Packaging and AGA Precision Systems aim to enhance product offerings and service capabilities in IT packaging and precision machining, potentially benefiting customers through expanded solutions and improved efficiency.
• **Suppliers**: The company has concentrations of suppliers, with 2 key suppliers representing 28% of inventory costs, posing a potential supply chain risk if relationships are disrupted.
• **Creditors**: The company's obligations under the equity line of credit are secured by assets and equity interests of subsidiaries (AGA and Pacific Sun), giving the institutional investor a first-position security interest, which could impact other creditors in case of default.

Next Steps

• File an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to evaluate EL-22 in combination with GLP-1 receptor agonists.
• Initiate clinical trials in the U.S. for EL-22, contingent upon FDA clearance of the IND submission.
• Continue to identify and acquire biotechnology assets and operating companies to expand and diversify the portfolio.
• Utilize clinical validation studies to strengthen the commercial potential and scientific credibility of portfolio companies' technologies.
• Evaluate potential spin-offs of wholly-owned subsidiaries to unlock shareholder value.
• Complete the evaluation of purchase price allocation and fair value of identifiable assets acquired and liabilities assumed for the Indarg Engineering, Inc. acquisition in subsequent reporting periods.

Key Dates

Recommendation

PMGC Holdings Inc. presents an extremely high-risk investment profile. The company's financial statements carry a 'going concern' warning, indicating a fundamental uncertainty about its ability to continue operations. It has a history of significant and increasing net losses, with an accumulated deficit of over $18 million. While the strategic shift to biotechnology and manufacturing acquisitions offers potential, the company's heavy reliance on continuous, dilutive capital raises (equity line, ATM, warrant inducements) to fund operations and acquisitions is a major concern. The terms of these financings, including discounted share issuances and secured debt, are highly unfavorable to existing common shareholders, leading to substantial dilution. Furthermore, the concentration of voting control in related parties raises corporate governance red flags. Given the severe financial distress, persistent losses, and ongoing need for dilutive capital, a seasoned investor would likely view this as a 'strong sell' due to the high probability of further capital erosion and potential for complete loss of investment.

Keywords

Biotechnology, Acquisitions, SEC Filing, S-1/A, PMGC Holdings, Northstrive Biosciences, EL-22, Obesity Treatment, Muscle Preservation, GLP-1 Agonists, Precision Machining, Specialty Packaging, Capital Raise, Equity Line of Credit, Warrants, Reverse Stock Split, Going Concern, Financial Performance, Corporate Governance, Risk Factors, Nasdaq